Evidence map›Paper›PMID 40823152›Full record

ArticleAging pathobiology and therapeutics2024

A change is needed in the landscape of preclinical models to test drugs that target aging.

Warren Ladiges

Abstract read
In one paragraph

Article in Aging pathobiology and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Warren LadigesDepartment of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.

Funding

Physical resilience is a predictor of healthy aging in miceR01AG057381 · NIA · UNIVERSITY OF WASHINGTON · PI Warren C LADIGES · 2017 to 2026
$4.6M
NIA NIH HHS R01 AG057381
6 · The paper itself

Abstract

Efficient and reproducible preclinical models for testing drugs or drug combinations that target aging are vital to develop a pipeline that results in a predictable outcome for geroscience research and geriatric medicine. Lifespan as a readout test in laboratory mice has been successful in identifying several drugs that robustly enhance healthy aging, and has provided impactful information for moving to clinical studies. However, it is a costly and time consuming process (about three years), and poorly designed to test drug combinations. Therefore, a more efficient pipeline is needed that would provide an increased number of drugs or drug combinations with promising and predictable outcomes for first in human studies in a shorter time frame. This editorial discusses an alternate system involving prescreening in an invertebrate model (the domestic house cricket) followed by short term cross sectional testing in aging mice. The time frame is about six months, and the system is simple enough to allow testing of multiple drugs concurrently. The cricket to mouse pipeline provides a logical and preclinical translational approach to identify drugs that have the potential to enhance human health at later ages of life.

Indexed as

Aging interventionaging micedrugs and drug combinationshouse cricketspreclinical animal modelstranslational drug testing

Identifiers

PMID40823152
PMCPMC12352505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.